{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:10:08Z","timestamp":1783825808017,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.phrs.2020.104757","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T14:02:10Z","timestamp":1584367330000},"page":"104757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["TGF-\u03b2 activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases"],"prefix":"10.1016","volume":"155","author":[{"given":"Irene","family":"Marafini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Troncone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10080","key":"10.1016\/j.phrs.2020.104757_bib0005","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"10080","key":"10.1016\/j.phrs.2020.104757_bib0010","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"7152","key":"10.1016\/j.phrs.2020.104757_bib0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"issue":"5717","key":"10.1016\/j.phrs.2020.104757_bib0020","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1106442","article-title":"Immunity, inflammation, and allergy in the gut","volume":"307","author":"Macdonald","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2020.104757_bib0025","first-page":"9","article-title":"Interrogating host immunity to predict treatment response in inflammatory bowel disease, Nature reviews","volume":"17","author":"Digby-Bell","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2020.104757_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fphar.2019.00305","article-title":"Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease","volume":"10","author":"Di Fusco","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2020.104757_bib0035","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","article-title":"Inflammatory cytokines: from discoveries to therapies in IBD","volume":"19","author":"Marafini","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2020.104757_bib0040","first-page":"269","article-title":"Current and emerging therapeutic targets for IBD, Nature reviews","volume":"14","author":"Neurath","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104757_bib0045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2020.104757_bib0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ibd.21417","article-title":"Long-term complications, extraintestinal manifestations, and mortality in adult Crohn\u2019s disease in population-based cohorts","volume":"17","author":"Peyrin-Biroulet","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.104757_bib0055","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3389\/fimmu.2018.01854","article-title":"Reciprocal regulation between Smad7 and Sirt1 in the gut","volume":"9","author":"Sedda","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.104757_bib0060","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3389\/fimmu.2018.01407","article-title":"Transforming growth Factor-beta1\/Smad7 in intestinal immunity, inflammation, and cancer","volume":"9","author":"Troncone","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104757_bib0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40259-018-0286-1","article-title":"Oligonucleotide-based therapies for inflammatory bowel disease","volume":"32","author":"Bevivino","year":"2018","journal-title":"BioDrugs: Clin. Immunother. Biopharm. Gene Ther."},{"issue":"5","key":"10.1016\/j.phrs.2020.104757_bib0070","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/07853890.2018.1490025","article-title":"Inflammatory bowel disease: new therapies from antisense oligonucleotides","volume":"50","author":"Marafini","year":"2018","journal-title":"Ann. Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.104757_bib0075","first-page":"603","article-title":"CCL20 is negatively regulated by TGF-beta1 in intestinal epithelial cells and reduced in Crohn\u2019s disease patients with a successful response to mongersen, a Smad7 antisense oligonucleotide","volume":"11","author":"Marafini","year":"2017","journal-title":"J. Crohns Colitis"},{"issue":"12","key":"10.1016\/j.phrs.2020.104757_bib0080","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1097\/MIB.0000000000000542","article-title":"The TGF-beta\/Smad system in IBD pathogenesis","volume":"21","author":"Sedda","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0085","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","article-title":"Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis","volume":"131","author":"Boirivant","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2020.104757_bib0090","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2008.12.053","article-title":"Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression","volume":"136","author":"Fantini","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.phrs.2020.104757_bib0095","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn\u2019s disease","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2020.104757_bib0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1172\/JCI12821","article-title":"Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease","volume":"108","author":"Monteleone","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0105","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1074\/jbc.M303654200","article-title":"A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation","volume":"279","author":"Monteleone","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2020.104757_bib0110","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2020.104757_bib0115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40265-015-0391-0","article-title":"Antisense approach to inflammatory bowel disease: prospects and challenges","volume":"75","author":"Marafini","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061276","article-title":"PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue","volume":"18","author":"Spadaccini","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.phrs.2020.104757_bib0125","first-page":"30005","article-title":"Effects of Apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"S1542-3565","author":"Danese","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.phrs.2020.104757_bib0130","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1517\/13543784.16.9.1489","article-title":"Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease","volume":"16","author":"Keshavarzian","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2020.104757_bib0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.gastro.2006.11.029","article-title":"A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis","volume":"132","author":"Schreiber","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.104757_bib0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.immunol.16.1.137","article-title":"Regulation of immune responses by TGF-beta","volume":"16","author":"Letterio","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"7090","key":"10.1016\/j.phrs.2020.104757_bib0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2020.104757_bib0150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1572-0241.2006.01010.x","article-title":"Fibrogenesis in Crohn\u2019s disease","volume":"102","author":"Burke","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"issue":"6659","key":"10.1016\/j.phrs.2020.104757_bib0160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/37284","article-title":"TGF-beta signalling from cell membrane to nucleus through SMAD proteins","volume":"390","author":"Heldin","year":"1997","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0092-8674(00)81696-7","article-title":"Smads: transcriptional activators of TGF-beta responses","volume":"95","author":"Derynck","year":"1998","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.phrs.2020.104757_bib0170","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/emboj\/17.11.3091","article-title":"Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene","volume":"17","author":"Dennler","year":"1998","journal-title":"EMBO J."},{"issue":"6397","key":"10.1016\/j.phrs.2020.104757_bib0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","article-title":"Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease","volume":"359","author":"Shull","year":"1992","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2020.104757_bib0180","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1074-7613(00)80170-3","article-title":"Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease","volume":"12","author":"Gorelik","year":"2000","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0185","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1084\/jem.183.6.2605","article-title":"Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance","volume":"183","author":"Neurath","year":"1996","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0190","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1084\/jem.183.6.2669","article-title":"A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells","volume":"183","author":"Powrie","year":"1996","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.104757_bib0195","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/emboj\/18.5.1280","article-title":"Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta","volume":"18","author":"Yang","year":"1999","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.phrs.2020.104757_bib0200","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.4049\/jimmunol.1502548","article-title":"TGF-beta signaling in dendritic cells governs colonic homeostasis by controlling epithelial differentiation and the luminal microbiota","volume":"196","author":"Ihara","year":"2016","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.104757_bib0205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/gut.2007.130922","article-title":"Blockade of transforming growth factor beta upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa","volume":"57","author":"Di Sabatino","year":"2008","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.phrs.2020.104757_bib0210","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.celrep.2019.07.065","article-title":"Smad7 controls immunoregulatory PDL2\/1-PD1 signaling in intestinal inflammation and autoimmunity","volume":"28","author":"Garo","year":"2019","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.phrs.2020.104757_bib0215","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1053\/j.gastro.2005.09.005","article-title":"Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease","volume":"129","author":"Monteleone","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0220","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/mi.2014.35","article-title":"Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut","volume":"7","author":"Caruso","year":"2014","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0225","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/ibd\/izy062","article-title":"Knockdown of Smad7 with a specific antisense oligonucleotide attenuates colitis and colitis-driven colonic fibrosis in mice","volume":"24","author":"Izzo","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"issue":"9","key":"10.1016\/j.phrs.2020.104757_bib0230","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/apt.12051","article-title":"A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn\u2019s disease","volume":"36","author":"Zorzi","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2020.104757_bib0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2017.08.035","article-title":"Effects of Mongersen (GED-0301) on endoscopic and clinical outcomes in patients with active Crohn\u2019s disease","volume":"154","author":"Feagan","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.104757_bib0240","article-title":"Mongersen (GED-0301) for active Crohn\u2019s disease: results of a phase 3 study","author":"Sands","year":"2019","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104757_bib0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production","volume":"63","author":"Eigler","year":"1998","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2020.104757_bib0250","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.intimp.2008.05.012","article-title":"A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells","volume":"8","author":"Ma","year":"2008","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2020.104757_bib0255","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.4049\/jimmunol.0803310","article-title":"Inhibition of cAMP degradation improves regulatory T cell-mediated suppression","volume":"182","author":"Bopp","year":"2009","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0260","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20062129","article-title":"Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression","volume":"204","author":"Bopp","year":"2007","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.104757_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056867","article-title":"The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3\/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice","volume":"8","author":"Rieder","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2020.104757_bib0270","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0002-9440(10)65087-0","article-title":"Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity","volume":"156","author":"Diaz-Granados","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104757_bib0275","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-3565(24)35257-7","article-title":"Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice","volume":"292","author":"Hartmann","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2020.104757_bib0280","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1124\/jpet.105.090837","article-title":"Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis","volume":"316","author":"Videla","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2020.104757_bib0285","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/jpet.102.039529","article-title":"The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice","volume":"305","author":"Loher","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2020.104757_bib0290","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/ibd.20524","article-title":"Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice","volume":"14","author":"Ichikawa","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.phrs.2020.104757_bib0295","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.crohns.2009.03.001","article-title":"CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease","volume":"3","author":"Gordon","year":"2009","journal-title":"J. Crohns Colitis"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820303285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820303285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:16:50Z","timestamp":1760912210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820303285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":59,"alternative-id":["S1043661820303285"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104757","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TGF-\u03b2 activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104757"}}